Molekule Consulting published new data in Pediatrics suggesting that children ages 8 to 11 with severe obesity receive off-label GLP-1 therapy, with annual GLP-1 prescribing rising from 0.03% in 2019 to 9.3% in 2026.

Molekule Consulting is the specialized intelligence partner for biopharma leaders who need to validate reality before committing capital. THE REALITY GAP Data rooms and public filings often present a sanitized view of an asset. We collect what is missing. We don't rely on assumptions; we stress-test your strategy against the ground truth of the clinical and commercial landscape. Our job is to find the hidden constraints—whether Regulatory, CMC, or Market Access—that impact the Net Present Value (NPV) of your asset. CORE CAPABILITIES Clinical & Development Intel We see past the press release. We validate investigator sentiment, enrollment velocity, and data integrity risks to give you a true read on competitor timelines. Commercial & Market Access We map the real payer landscape and formulary threats, distinguishing between a competitor's "announced" launch strategy and their actual ability to execute in the field. Lifecycle Defense (LoE) We model counter-strategies for Loss of Exclusivity events and generic/biosimilar entry, helping you structure a defense before erosion begins. Strategic War-Gaming We simulate Launch vs. Counter-Launch scenarios to force leadership to confront the consequences of competitor interference. OUR STANDARD We do not speculate. We provide the clarity required to make high-stakes decisions. Note: To protect our collection network, we do not publish client lists. Please direct inquiries to the contact below. Contact: info@molekuleconsulting.com